Haverich A, Hirt S W, Wahlers T, Schäfers H J, Zink C, Borst H G
Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.
J Heart Lung Transplant. 1994 Jan-Feb;13(1 Pt 1):48-54; discussion 55.
In selected cases with either acute or chronic graft failure after lung or heart-lung transplantation, retransplantation remains the only therapeutic option. Since December 1987, we have performed a total of 110 single lung, bilateral lung, and combined heart-lung transplantations in 102 patients including five early and four late retransplantations in eight patients. Early retransplantation was indicated for severe reperfusion injury after single lung transplantation (n = 2) or heart-lung transplantation (n = 1), for persistent pulmonary hypertension caused by an unrecognized aortopulmonary window (n = 1), for central airway necrosis, and for contralateral pulmonary artery bleeding after bilateral lung transplantation (n = 1). Two of these patients after single lung transplantation were bridged with extracorporeal membrane oxygenation for 9 and 11 days until single lung retransplantation. Three patients underwent late single lung retransplantation 14, 24, and 26 months after single lung transplantation (n = 2) or heart-lung transplantation (n = 1) for chronic rejection, and an additional patient was treated successfully by bilateral lung retransplantation for obliterative bronchiolitis and central airway stenosis 26 months after bilateral lung transplantation. Two patients died 19 and 140 days, respectively, after acute retransplantation because of early graft failure and progressive rejection, respectively, while the other patients were discharged from the hospital. Mortality was 22.2% in the retransplantation group versus 15.1% (11 of 73 patients) undergoing primary single lung transplantation or bilateral lung transplantation (not significant). Patient survival after retransplantation ranged between 159 and 993 days (median, 453 days). Duration of postoperative ventilation was markedly prolonged in patients who underwent retransplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
在肺移植或心肺联合移植后出现急性或慢性移植失败的特定病例中,再次移植仍然是唯一的治疗选择。自1987年12月以来,我们共对102例患者进行了110次单肺、双肺及心肺联合移植,其中8例患者进行了5例早期和4例晚期再次移植。早期再次移植的指征包括单肺移植(n = 2)或心肺联合移植(n = 1)后严重的再灌注损伤、未被识别的主肺动脉窗导致的持续性肺动脉高压(n = 1)、中央气道坏死以及双肺移植后对侧肺动脉出血(n = 1)。这两例单肺移植后的患者通过体外膜肺氧合桥接9天和11天,直至进行单肺再次移植。3例患者在单肺移植(n = 2)或心肺联合移植(n = 1)后14、24和26个月因慢性排斥反应接受了晚期单肺再次移植,另外1例患者在双肺移植26个月后因闭塞性细支气管炎和中央气道狭窄成功接受了双肺再次移植。2例患者在急性再次移植后分别于19天和140天死亡,原因分别是早期移植失败和进行性排斥反应,而其他患者均已出院。再次移植组的死亡率为22.2%,而接受初次单肺移植或双肺移植的患者死亡率为15.1%(73例患者中有11例)(无显著差异)。再次移植后患者的生存时间在159天至993天之间(中位数为453天)。接受再次移植的患者术后通气时间明显延长。(摘要截取自250字)